Development of Secondary Acute Myeloid Leukemia in a Pediatric Patient Concurrently Receiving Primary Therapy for Ewing SarcomaMcNew, Brandon R. MD*,†; Darbro, Benjamin W. MD, PhD*; Ma, Deqin MD, PhD*; Gordon, David J. MD, PhD*Journal of Pediatric Hematology/Oncology: October 2017 - Volume 39 - Issue 7 - p e370–e372 doi: 10.1097/MPH.0000000000000924 Online Articles: Clinical and Laboratory Observations Abstract Author Information Ewing sarcoma is a pediatric bone and soft tissue sarcoma that requires intensive therapy, which can cause secondary malignancies. We present a rare case of early, treatment-related AML in a pediatric patient concurrently receiving primary therapy for Ewing sarcoma. Despite AML-directed therapy, our patient died secondary to complications of hyperleukocytosis. Cytogenetic and mutation profiling of the leukemia cells revealed the DNA-topoisomerase-II-inhibitor-associated t(9;11)(p22;q23) translocation and clonal KRAS and BRAF mutations. This report highlights the importance of monitoring for treatment-related effects in cancer therapy, as well as the need for novel, less toxic approaches in Ewing sarcoma therapy. *University of Iowa Hospitals and Clinics, Iowa City, IA †Blank Children’s Cancer and Blood Disorder Center, Des Moines, IA The authors declare no conflict of interest. Reprints: Brandon R. McNew, MD, 1200 Pleasant St, Des Moines, IA 50309 (e-mail: Brandon.firstname.lastname@example.org). Received December 7, 2015 Accepted May 16, 2016 Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved.